CSLLY vs GRFS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GRFS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CSLLY and GRFS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CSLLY and GRFS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CSL Limited is one of the world's largest biotechnology companies and is listed on the Australian Securities Exchange, with US investors able to hold it through the CSLLY American Depositary Receipt. The group runs three businesses. CSL Behring, the largest at roughly US$11.4 billion of FY26 revenue, collects blood plasma through one of the biggest donor-center networks in the world and fractionates it into therapies such as immunoglobulins (used for immune deficiencies and neurological conditions), albumin, haemophilia treatments and specialty products like the gene therapy HEMGENIX and the hereditary angioedema drug ANDEMBRY. CSL Seqirus, at about US$2.0 billion, is one of the largest influenza vaccine makers globally, with egg-based, cell-based and adjuvanted vaccines and a pandemic-preparedness role for several governments. CSL Vifor, at about US$2.4 billion, sells iron-deficiency and kidney-disease medicines and came with the roughly US$11.7 billion acquisition of Vifor Pharma in 2022. CSL reports in US dollars even though its home listing is in Australian dollars.

Full CSLLY guide

Grifols, S.A. is a Spanish healthcare company founded in Barcelona in 1909 and one of the three dominant players in the global blood-plasma industry, alongside CSL and Takeda. It collects human plasma through a large network of donation centers (heavily concentrated in the United States) and fractionates it into therapies, most importantly immunoglobulins (IVIG and subcutaneous Ig) used for immune deficiencies and neurological conditions, plus albumin, alpha-1 antitrypsin, and clotting factors. The business also includes a diagnostics division (blood typing, transfusion screening) and a bio-supplies arm. Revenue comes from selling these plasma-derived medicines to hospitals, specialty pharmacies, and health systems worldwide, with the immunoglobulin franchise the single largest and fastest-growing driver. Grifols trades on the Spanish exchanges under Class A (GRF) and non-voting Class B (GRF.P) shares, and in the US as ADRs under the ticker GRFS.

Full GRFS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CSLLY drivers: Immunoglobulin recovery at CSL Behring; Plasma cost and margin rebuild.
• GRFS drivers: Immunoglobulin demand and volume growth; Margin recovery from lower cost-per-liter.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most immediate risk is that immunoglobulin demand stays soft or that competitors such as Grifols, Takeda and Octapharma price aggressively, which would undercut the FY27 guidance the recent rebound is built on. For GRFS, grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CSLLY if you believe its drivers more; GRFS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CSLLY and GRFS guides.

CSLLY. CSL reports in US dollars, which makes its earnings directly comparable to the CSLLY price once the four-ADRs-per-share ratio is applied: one ASX share at about A$185 is roughly US$129, or about US$32 per ADR. At around 20 times underlying earnings, CSL trades well below the 30 to 40 times multiple it commanded for most of the last decade, which reflects both slower expected growth and lower confidence after the guidance cuts. FY26 dividends totalled roughly US$2.92 per share (an interim of about US$1.30 and a final of US$1.62), and the company is continuing an on-market buyback of about US$1.1 billion in FY27. The statutory loss is driven by non-cash impairments and restructuring charges, while operating cash flow held near US$3.5 billion.

GRFS. As of October 16, 2026 the ADR trades near $7.72, about 10x trailing and 5x forward earnings and roughly 0.7x sales, a deeper discount to plasma peers like CSL than in mid-2026 after a weak second quarter. The low forward multiple rests on analysts expecting 2026 EPS growth of about 35% and 2027 growth of about 24%, while roughly EUR 9.4 billion of debt means much of the enterprise value still sits with lenders, which is why deleveraging remains the key equity lever. The two analysts in Yahoo's consensus rate the ADR a buy with a mean target near $10.86.

Headline figures (approximate, October 2026): CSLLY shows revenue (fy26, year to june 2026) ~US$15.8 billion (down ~1%), underlying npata (fy26) ~US$3.1 billion (down ~2%), statutory result (fy26) ~US$2.6 billion loss after ~US$7.1 billion pre-tax impairments, fy27 guidance ~5% underlying NPAT growth, revenue broadly flat at constant currency; GRFS shows revenue (ttm) ~EUR 7.4 billion (Q2 2026 ~-0.9% YoY), net income (ttm) ~EUR 452 million (FY2025 ~EUR 402 million), q2 2026 eps vs estimate ~$0.17 vs ~$0.28 (miss), gross / operating margin (ttm) ~37.8% / ~15.9%.

CSLLY and GRFS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CSLLY and GRFS exposure against your real portfolio. It is not an investment adviser.